UBS Maintains Neutral on Center, Lowers Price Target to $65
UBS maintains Center (NYSE:CSR) with a Neutral and lowers the price target from $68 to $65.
Stocks · News reference
Piper Sandler analyst Alexander Goldfarb maintains Center (NYSE:CSR) with a Neutral and lowers the price target from $58 to $56.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS maintains Center (NYSE:CSR) with a Neutral and lowers the price target from $68 to $65.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.
Filed: 2026-09-23 AccNo: 0001140361-26-037453 Size: 239 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits